{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Emerging Biotech Leader","title":"Launch & Leadership In Early Biotech - Adriana Valenciano and Jacqui Levine : 23 ","html":"","width":"100%","height":180,"duration":1604,"description":"“It's not always smooth sailing or a straight line path. So being able to address those different inflection points, being able to resource accordingly, flex in, flex out, and really focus on ‘what are the most important priorities?’ Make sure you're addressing those, the ‘must haves’ versus the ‘nice to haves.’” Jacqui Levine, Vice President, SSI Strategy \n\nPreparing for a biotech launch now or at some point in the future? Then you’ll want to bookmark Episode 23 of the Emerging Biotech Leader, which serves as a mini masterclass on how to think about launching as well as what's to follow post-launch. \n\nSSI’s Adriana Valenciano, Senior Vice President, is host again alongside Ramin and a new voice to the podcast, Jacqui Levine, Vice President of SSI Strategy. Based on their collective experience, Adriana, Ramin, and Jacqui provide ways to prepare for all stages of launching and how to understand everything that’s required. \n\nAs a preview of what’s to come in this discussion, our trio cover:\nThe difference (and similarities) between launching in biotech vs Big Pharma\nWhat role communication plays in the launch process\nHow to think strategically and also execute\nPresenting to the board and\nWhat can put your launch at risk\n\nShare this episode with colleagues and peers–and without further ado, let’s get you into the recap. \n\nOn Biotech vs Big Pharma Launches: What’s Different? What’s Similar? \nTo kick things off, Adriana, Ramin, and Jacqui discussed the distinctions between launching in biotech vs Big Pharma as well as what was similar.  \n\nOn the latter, Ramin did share that while Big Pharma comparatively has bigger budgets, increased headcount, and brand recognition, the skill of prudence and monitoring one’s P&L with attention and discretion is always table stakes regardless of the launch company’s size. “You will have more resources in Big Pharma, but they aren’t unlimited.”\n\nGiven their smaller budgets, biotechs do have to plan for different ways of resourcing...","thumbnail_url":"https://img.transistorcdn.com/ifry0mqC60CO4NUZn9GSCTvcoZ9yKEWu4twnqKmJQQ0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS80NzEy/MTZiMmZlODIyZDI4/OTliMGJiOWQ0ZDUx/MDhmNi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}